Page last updated: 2024-12-08
7-oxodehydroepiandrosterone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
7-ketodehydroepiandrosterone : A 3beta-hydroxy-Delta(5)-steroid that is dehydroepiandrosterone carrying an additional oxo group at position 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 193313 |
CHEBI ID | 183808 |
SCHEMBL ID | 600097 |
MeSH ID | M0043740 |
Synonyms (40)
Synonym |
---|
AC-13409 |
3-hydroxy-10,13-dimethyl-2,3,4,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-7,17-dione |
7-oxodehydroepiandrosterone |
AKOS005146223 |
3beta-hydroxy-5-androstene-7,17-dione |
5-androsten-3beta-ol-7,17-dione |
566-19-8 |
7-ketoprasterone |
7-oxo-dehydroepiandrosterone |
CHEBI:183808 |
7-ketodehydroepiandrosterone |
3beta-hydroxyandrost-5-ene-7,17-dione |
7-oxo-dhea |
7-keto-dehydroepiandrosterone |
7-oxoprasterone |
7-keto-dhea |
7-keto |
A831119 |
(3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-2,3,4,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-7,17-dione |
2334ljd2e9 , |
dhea, 7-keto- |
unii-2334ljd2e9 |
SCHEMBL600097 |
7-oxo-prasterone |
androst-5-ene-7,17-dione, 3-hydroxy-, (3.beta.)- |
7-keto-dehydroepiandrosterone [who-dd] |
(3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-3,4,9,10,11,12,13,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-7,17(2h,8h)-dione |
KPRGOTLNGIBVFL-GINZOMEDSA-N |
7-oxo dhea |
Q-200562 |
7-keto dhea |
androst-5-ene-7,17-dione, 3-hydroxy-, (3b)- |
mfcd00198500 |
3-hydroxy-10,13-dimethyl-3,4,9,10,11,12,13,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-7,17(2h,8h)-dione |
DS-8228 |
Q4642869 |
AMY27580 |
DTXSID801024029 |
PD076289 |
(3as,3br,7s,9ar,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-1,4-dione |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (3)
Role | Description |
---|---|
human blood serum metabolite | Any metabolite (endogenous or exogenous) found in human blood serum samples. |
nutraceutical | A product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. |
prohormone | Any intra-glandular substance that acts as a precursor of a hormone, usually having minimal hormonal effect itself. Prohormones generally help in amplifying the effect of existing hormones. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
Class | Description |
---|---|
17-oxo steroid | Any oxo steroid carrying the oxo group at position 17. |
3beta-hydroxy-Delta(5)-steroid | Any 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6. |
androstanoid | Any steroid based on an androstane skeleton and its derivatives. |
7-oxo steroid | Any oxo steroid carrying an oxo group at position 7. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (18)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (11.11) | 18.2507 |
2000's | 6 (33.33) | 29.6817 |
2010's | 7 (38.89) | 24.3611 |
2020's | 3 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.83) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (16.67%) | 5.53% |
Reviews | 1 (5.56%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (77.78%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |